Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27452484 | 0.83 | ADORA2A (0.40) | KDM4EPKMALDH1A1HPGDKMT2A | |
| SCHEMBL12355760 | 0.77 | KDM4E (0.43) | KDM4EPKMALDH1A1HPGDTSHR | |
| SCHEMBL26927225 | 0.74 | KDM4E (0.41) | KDM4EPKMALDH1A1HPGDTSHR | |
| SCHEMBL12768618 | 0.74 | GPR35 (0.41) | KDM4EPKMALDH1A1HPGDTSHR | |
| SCHEMBL20907651 | 0.74 | KDM4E (0.36) | KDM4EPKMALDH1A1HPGDTSHR | |
| SCHEMBL8305360 | 0.74 | ALDH1A1 (0.48) | KDM4EPKMALDH1A1HPGDTSHR | |
| SCHEMBL11755260 | 0.72 | PLA2G2A (0.40) | ALDH1A1HPGDKMT2AMAPT | |
| SCHEMBL10985449 | 0.71 | GABRP (0.41) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11003416 | 0.71 | ALDH1A1 (0.53) | KDM4EPKMALDH1A1HPGDKMT2A | |
| SCHEMBL8188239 | 0.70 | KDM4E (0.40) | KDM4EPKMALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101027309-B | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer | ASTRAZENECA AB SE | 2010-10-27 | — | — | CN | disclosed |
| EP-1781673-B1 | SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-7498333-B2 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| CN-101027309-A | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer | ASTRAZENECA AB (SE) | 2007-08-29 | — | — | CN | disclosed |
| CN-101023086-A | Selectively fused heterocyclic ring and use thereof | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | CN | disclosed |
| EP-1781674-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTION OF CANCER | AstraZeneca AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | ASTRAZENECA AB (SE) | 2006-03-23 | — | — | US | disclosed |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
| WO-2006018628-A1 | ENANTIOMERS OF SELECTED FUSED PYRIMIDONES AND USES IN THE TREATMENT AND PREVENTI ON OF CANCER | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249636-A1 | Selected Fused Heterocyclics and Uses Thereof | SDHA, CYP11B2, NQO1 | KDM4E 2760/4885PKM 1157/4885ALDH1A1 293/4885 |
| US-20060063751-A1 | Novel fused heterocycles and uses thereof | RB1, CDK19, PRMT9 | KDM4E 1170/4885PKM 2567/4885ALDH1A1 672/4885 |
| US-20080153854-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | RB1, CDK19, PRMT9 | KDM4E 1170/4885PKM 2567/4885ALDH1A1 672/4885 |
| US-20080293744-A1 | Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer | DHFR, DPYD, TYMS | KDM4E 3363/4885PKM 1828/4885ALDH1A1 172/4885 |
| US-20060041128-A1 | Selected fused heterocyclics and uses thereof | SDHA, CYP11B2, NQO1 | KDM4E 2760/4885PKM 1157/4885ALDH1A1 293/4885 |
| US-20090099210-A1 | ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF | CYP11B2, HCCS, CYP11B1 | KDM4E 2980/4885PKM 1654/4885ALDH1A1 214/4885 |
| US-20060041129-A1 | Enantiomers of selected fused heterocyclics and uses thereof | CYP11B2, HCCS, CYP11B1 | KDM4E 2980/4885PKM 1654/4885ALDH1A1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.